Non-small cell lung cancer
Conditions
Interventions
A single arm:Arotinib combined with radiotherapy
Sponsors
Clinical Trial Management Public Platform
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18-80 years old; gender is not limited; ECoG score <= 3. 2. Stage III NSCLC confirmed by histology or cytology (according to AJCC 8th Edition) which is inoperable or refused to be operated; 3. Patients with wild-type genes or patients without previous use of PD1 or PDL1 immunosuppressants; 4. The damage caused by other treatments has recovered, and the end of chemotherapy is more than 4 weeks; 5. No serious cardiovascular and cerebrovascular disease, normal liver and kidney function. 6. The subjects volunteered to join the study and signed informed consent, with good compliance and follow-up.
Exclusion criteria
Exclusion criteria: 1. The patients with EGFR, ALK and ros1 gene mutation are suitable for targeted therapy; 2. Patients who can not accept radical radiotherapy for various reasons; 3. Non small cell lung cancer patients with hemoptysis (> 50 ml / day); tumor with cavity or obvious necrosis; or imaging showed that important blood vessels had been invaded by tumor or researchers determined that tumor might invade important blood vessels during follow-up, causing fatal bleeding; 4. There are obvious factors affecting oral drug absorption, such as inability to swallow, chronic diarrhea and intestinal obstruction; 5. The estimated survival time was less than 6 months.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival, PFS;overall survival, OS; | — |
Primary
| Measure | Time frame |
|---|---|
| Objective response rate, ORR;Disease Control Rate, DCR; | — |
Countries
China
Contacts
Public ContactNingpeng
Baoji Gaoxin Hospital
Outcome results
None listed